This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
by Zacks Equity Research
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
Top Research Reports for Alphabet, Bank of America & PepsiCo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Bank of America (BAC), and PepsiCo (PEP).
Here's Why Eli Lilly (LLY) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Big Pharma Players on Strong Footing Ahead of Q4: 4 Picks
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately and looks well poised for Q4. Here are four stocks from the space that investors may consider betting on.
Novartis to Cut Over 2000 Jobs, Focus on Higher Value Drugs
by Zacks Equity Research
Novartis (NVS) plans to lay off about 2000 jobs in Switzerland and the United Kingdom in order to focus on innovative, specialized and personalized medicines than on mass-produced products.
Glaxo's Tuberculosis Vaccine Positive in Mid-Stage Study
by Zacks Equity Research
Glaxo's (GSK) vaccine candidate, M72/AS01E, achieves significant reduction in incidence of pulmonary tuberculosis in HIV-negative patients with latent tuberculosis infection.
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
J&J's Esketamine Fails to Meet Endpoint in Phase III Study
by Zacks Equity Research
J&J's (JNJ) late-stage candidate, esketamine nasal spray, fails to show statistical significance for the primary endpoint in a phase III study on patients with treatment-resistant depression.
Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion
by Zacks Equity Research
Eli Lilly's (LLY) CGRP antibody Emgality gains a positive view from CHMP for the treatment of migraine in adults, who encounter minimum four migraine spells a month.
AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.
Market Rallies Despite Trade Worries: 5 Blue-Chip Picks
by Nalak Das
The current momentum in stock markets can primarily attributed to large-cap blue-chip stocks as investors shrugged off trade war jitters.
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
by Zacks Equity Research
Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
by Zacks Equity Research
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff
by Zacks Equity Research
Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.
Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern
by Zacks Equity Research
Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
by Zacks Equity Research
Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.
Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval
by Zacks Equity Research
Teva Pharmaceutical's (TEVA) anti-CGRP drug, Ajovy, gets FDA nod as a preventive treatment of migraine in adult patients.
Allergan Frown Lines Study Passes Test on Higher Botox Dose
by Zacks Equity Research
Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
by Zacks Equity Research
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
Roche's Child Arthritis Drug's New Formulation Gets FDA Nod
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.
AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
by Zacks Equity Research
AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FLQL
Why Eli Lilly (LLY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Merck's Antibacterial Drug Succeeds in Label Expansion Study
by Zacks Equity Research
Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.
AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.